MiNK Therapeutics Files 8-K on Shareholder Votes
Ticker: INKT · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1840229
Sentiment: neutral
Topics: corporate-governance, filing
TL;DR
MiNK Therapeutics filed an 8-K on shareholder votes. Keep an eye on governance changes.
AI Summary
MiNK Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 12, 2024. The company, formerly known as AgenTus Therapeutics, Inc. until January 12, 2021, is incorporated in Delaware and has its principal executive offices in New York, NY.
Why It Matters
This filing indicates that important decisions requiring shareholder approval have been made or are being reported, which could impact the company's strategic direction and governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of matters submitted to a vote of security holders, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former company name
- 20210112 (date) — Date of name change
- 20240612 (date) — Date of earliest event reported
- 20240617 (date) — Filing date
FAQ
What specific matters were submitted to a vote of MiNK Therapeutics' security holders?
The filing indicates that matters were submitted to a vote, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 12, 2024.
What is the current principal executive office address for MiNK Therapeutics, Inc.?
The principal executive offices are located at 149 Fifth Avenue, Suite 500, New York, New York, 10010.
When did MiNK Therapeutics, Inc. change its name from AgenTus Therapeutics, Inc.?
The company changed its name from AgenTus Therapeutics, Inc. on January 12, 2021.
Under which section of the Securities Exchange Act of 1934 is this Current Report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-17 16:05:10
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share INKT The Nasdaq Stock Mar
Filing Documents
- inkt-20240612.htm (8-K) — 47KB
- 0000950170-24-074233.txt ( ) — 161KB
- inkt-20240612.xsd (EX-101.SCH) — 25KB
- inkt-20240612_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting of Stockholders (the "Annual Meeting") on June 12, 2024. A total of 28,359,271 shares of common stock, representing 81.71% of the shares outstanding and eligible to vote and constituting a quorum, were present at the Annual Meeting or represented by valid proxies. At the Annual Meeting, the Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2024: (i) to elect Brian Corvese and Peter Behner as Class III directors, each for a term of three years expiring at the 2027 Annual Meeting of Stockholders ("Proposal 1") and (ii) to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 ("Proposal 2"). The Company's stockholders elected each of the Class III director nominees nominated for election in Proposal 1 at the Annual Meeting. The Company's stockholders voted for the Class III directors as follows: Class III Director Nominees For Against Withheld Broker Non-Votes Brian Corvese 24,620,089 0 374,259 3,364,923 Peter Behner 24,699,681 0 294,667 3,364,923 The Company's stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Withheld Broker Non-Votes 28,242,636 110,437 6,198 NA
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MiNK Therapeutics, Inc. Date: June 17, 2024 By: /s/ Jennifer S. Buell, Ph.D. Jennifer S. Buell, Ph.D. President and Chief Executive Officer